INNOVIVA, INC. Debt Securities, Available-for-sale
INNOVIVA, INC. (INVA) had Debt Securities, Available-for-sale of $548.48 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale $548.48M.
- 2026-03-31: Debt Securities, Available-for-sale $582.37M.
- 2025-12-31: Debt Securities, Available-for-sale $530.28M.
- 2025-09-30: Debt Securities, Available-for-sale $442.27M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $548.48M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $582.37M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $530.28M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $442.27M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $383.23M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $299.42M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $289.44M 10-K · filed 2026-02-25 |
| 2024-09-30 | $252.26M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $201.45M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $151.84M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $170.71M 10-K · filed 2025-02-26 |
| 2023-09-30 | $134.29M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $118.93M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $75.43M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $263.47M 10-K/A · filed 2024-03-05 |
| 2021-12-31 | $145.13M 10-K · filed 2023-02-28 |
| 2021-09-30 | $78.03M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $2.84M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $248.93M 10-Q · filed 2021-04-28 |
| 2020-12-31 | $204.81M 10-K/A · filed 2022-03-17 |
| 2020-09-30 | $430.14M 10-Q · filed 2020-10-28 |
| 2020-06-30 | $382.47M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $348.27M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $306.74M 10-K · filed 2021-02-25 |
| 2019-09-30 | $247.46M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $228.29M 10-Q · filed 2019-07-24 |
| 2019-03-31 | $180.27M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $108.97M 10-K · filed 2020-02-19 |
| 2018-09-30 | $50.55M 10-Q · filed 2018-10-31 |
| 2018-06-30 | $101.74M 10-Q · filed 2018-07-26 |
| 2018-03-31 | $51.43M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $122.71M 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |